Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending

Simply Wall St.04-08

Celcuity Inc. recently reported fourth-quarter 2025 results showing a net loss of US$50.97 million, with basic loss per share from continuing operations of US$0.97, and a full-year 2025 net loss of US...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625966303?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-08 04:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625966303","market":"sg","top_or_hot":-1,"title":"Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending","media":"Simply Wall St.","content":"<div>\n<p>Celcuity Inc. recently reported fourth-quarter 2025 results showing a net loss of US$50.97 million, with basic loss per share from continuing operations of US$0.97, and a full-year 2025 net loss of US...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/why-celcuity-celc-is-up-55-after-reporting-wider-2025-losses\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-08 04:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/why-celcuity-celc-is-up-55-after-reporting-wider-2025-losses><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Celcuity Inc. recently reported fourth-quarter 2025 results showing a net loss of US$50.97 million, with basic loss per share from continuing operations of US$0.97, and a full-year 2025 net loss of US...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/why-celcuity-celc-is-up-55-after-reporting-wider-2025-losses\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/why-celcuity-celc-is-up-55-after-reporting-wider-2025-losses","article_id":"2625966303","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/why-celcuity-celc-is-up-55-after-reporting-wider-2025-losses","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625966303","pubTimestamp":1775593202,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Celcuity Inc. recently reported fourth-quarter 2025 results showing a net loss of US$50.97 million, with basic loss per share from continuing operations of US$0.97, and a full-year 2025 net loss of US$177.04 million, or US$3.79 per share, both higher than the prior year.\nThe sharp year-on-year increase in reported net loss highlights the cost of Celcuity’s ongoing development and commercialization efforts as it remains a pre-revenue, clinical-stage biotechnology company.\nWith losses widening...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CELC":"Celcuity Inc"},"translate_title":"为什么Celcuity(CELC)在报告2025年持续研发支出造成更大损失后上涨5.5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":1.5},"content_text":"Celcuity Inc. recently reported fourth-quarter 2025 results showing a net loss of US$50.97 million, with basic loss per share from continuing operations of US$0.97, and a full-year 2025 net loss of US$177.04 million, or US$3.79 per share, both higher than the prior year. The sharp year-on-year increase in reported net loss highlights the cost of Celcuity’s ongoing development and commercialization efforts as it remains a pre-revenue, clinical-stage biotechnology company. With losses widening in 2025, we’ll now examine how this growing cash burn affects Celcuity’s previously outlined investment narrative and risk profile. The latest GPUs need a type of rare earth metal called Neodymium and there are only 27 companies in the world exploring or producing it. Find the list for free.AdvertisementCelcuity Investment Narrative RecapTo own Celcuity today, you have to believe gedatolisib can move from promising late stage data to an approved, commercially relevant cancer therapy. The latest results, with a full year 2025 net loss of US$177.04 million, increase focus on cash burn, but do not directly change the near term catalyst: the FDA’s priority review of the gedatolisib NDA. The biggest current risk remains that regulatory timing or outcomes differ from expectations, prolonging losses. The most relevant recent announcement alongside these results is the FDA’s January 2026 acceptance of Celcuity’s NDA for gedatolisib, with Priority Review and a July 17, 2026 PDUFA date. That filing, supported by the published VIKTORIA 1 data, is central to the story because it could turn today’s pre revenue profile into future product revenue. Against this backdrop, the widening losses underscore how dependent the thesis is on a successful regulatory outcome. But while the upside hinges on gedatolisib’s approval, investors should also be aware of the growing cash burn and financing obligations that... Read the full narrative on Celcuity (it's free!)Celcuity's narrative projects $607.1 million revenue and $152.4 million earnings by 2029. This implies a $315.1 million earnings increase from -$162.7 million today.Uncover how Celcuity's forecasts yield a $116.70 fair value, in line with its current price.Exploring Other PerspectivesCELC 1-Year Stock Price Chart Some of the lowest ranked analysts were assuming about US$414.4 million of revenue and US$129.7 million of earnings by 2029, a far more cautious path than narratives that emphasize faster uptake or broader indications. This new loss profile could shift those expectations again and it is worth weighing how different these views are when you decide which story you believe.Explore 3 other fair value estimates on Celcuity - why the stock might be worth just $116.70!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Celcuity research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free Celcuity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celcuity's overall financial health at a glance.Contemplating Other Strategies?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Find 62 companies with promising cash flow potential yet trading below their fair value.AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625966303","isCrawlerRequest":true}